Immune Thrombocytopenic Purpura: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

PUNE, INDIA, September 26, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Complete Report @ https://www.wiseguyreports.com/reports/649789-idiopathic-thrombocytopenic-purpura-immune-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Get Sample Report @ https://www.wiseguyreports.com/sample-request/649789-idiopathic-thrombocytopenic-purpura-immune-review-h2-2016

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/649789-idiopathic-thrombocytopenic-purpura-immune-review-h2-2016

Table of Content

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18
3SBio Inc. 18
AkaRx Inc 19
Amgen Inc. 20
arGEN-X BV 21
Boehringer Ingelheim GmbH 22
Bristol-Myers Squibb Company 23
Genosco 24
Hansa Medical AB 25
Immunomedics, Inc. 26
Intas Pharmaceuticals Ltd. 27
Jiangsu Hengrui Medicine Co., Ltd. 28
Merck & Co., Inc. 29
Momenta Pharmaceuticals, Inc. 30
Novartis AG 31
Pfizer Inc. 32
PhytoHealth Corporation 33
Protalex, Inc. 34
Rigel Pharmaceuticals, Inc. 35
Shire Plc 36
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ARGX-113 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
avatrombopag - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
BI-655064 - Drug Profile 51
Continued…

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649789

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here